Litigation Details for Celgene Corporation v. Teva Pharmaceuticals USA, Inc. (D. Del. 2015)

« Back to Dashboard

Celgene Corporation v. Teva Pharmaceuticals USA, Inc. (D. Del. 2015)

Docket		Date Filed	2015-12-10
Court	District Court, D. Delaware	Date Terminated	2016-08-08
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,608,280; 7,611,724
Link to Docket	External link to docket

Details for Celgene Corporation v. Teva Pharmaceuticals USA, Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-12-10				External link to document
2015-12-09	1		United States Patent Nos. 7,608,280 (the “’280 patent”) and 7,611,724 (the “’724 patent”) (collectively… This is an action for patent infringement under the patent laws of the United States, 35 U.S.C… THE PATENTS-IN-SUIT 8. On October 27, 2009, the United States Patent and Trademark…lawfully issued the ’280 patent, titled “Method of Producing FR901228.” The ’280 patent is assigned to Astellas…United States Patent and Trademark Office (“USPTO”) duly and lawfully issued the ’724 patent, titled “Method	External link to document
2015-12-09	25		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,608,280 B2; 7,611,724 B2. (…2015 8 August 2016 1:15-cv-01143 830 Patent None District Court, D. Delaware	External link to document
2015-12-09	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,608,280 B2; 7,611,724 B2. (…2015 8 August 2016 1:15-cv-01143 830 Patent None District Court, D. Delaware	External link to document

Celgene Corporation v. Teva Pharmaceuticals USA, Inc. Litigation Summary and Patent Analysis

Last updated: August 13, 2026

Celgene Corporation sued Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the District of Delaware after Teva filed an abbreviated new drug application seeking approval for generic lenalidomide, the active ingredient in Revlimid. The case, No. 1:15-cv-01143, was part of Celgene's broader patent campaign against prospective generic manufacturers.

The dispute ended through a settlement rather than a public trial judgment. The agreement preserved Celgene's commercial protection for Revlimid while permitting Teva to enter the lenalidomide market under negotiated conditions. Teva later launched generic lenalidomide in the United States in 2022, subject to the commercial and distribution restrictions associated with the settlement and FDA requirements.

What drug and regulatory filing were at issue in Celgene v. Teva?

The case concerned lenalidomide, the active pharmaceutical ingredient in Revlimid.

Item	Details
Brand	Revlimid
Active ingredient	Lenalidomide
Brand company	Celgene Corporation, later acquired by Bristol Myers Squibb
Defendant	Teva Pharmaceuticals USA, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-01143
Legal basis	Hatch-Waxman patent infringement litigation
FDA pathway	Abbreviated New Drug Application
Dosage forms	Oral capsules
Major indications	Multiple myeloma, myelodysplastic syndromes associated with deletion 5q, and mantle cell lymphoma in specified settings
Distribution controls	Lenalidomide REMS and restricted distribution requirements

Teva's ANDA certification triggered Celgene's infringement action under the Hatch-Waxman framework. The lawsuit allowed the FDA to stay approval of the ANDA for up to 30 months, subject to earlier resolution or expiration of the relevant regulatory period. The complaint alleged that commercial manufacture, use, sale, or importation of Teva's proposed product would infringe Celgene patent rights listed for Revlimid or otherwise asserted in the litigation. (U.S. District Court for the District of Delaware, 2015)

What patents protected Revlimid in the Teva litigation?

Celgene's Revlimid patent estate combined composition, formulation, method-of-use, and risk-management protections. The estate was materially broader than a single compound patent.

Public Orange Book and patent records identify the following patent categories as relevant to Revlimid protection:

Patent category	Protection	Commercial purpose
Compound patents	Lenalidomide and related chemical subject matter	Core active-ingredient protection
Formulation patents	Pharmaceutical compositions and dosage forms	Protection against alternative capsule or formulation designs
Method-of-use patents	Treatment of multiple myeloma and hematologic disorders	Indication-specific infringement claims
Solid-form and process patents	Physical forms, preparation, or manufacturing methods	Added barriers to substitution and production
Distribution-system patents and controls	Safe-use and restricted-dispensing systems	Support for controlled distribution of lenalidomide

The important patents associated with Revlimid included U.S. Patent No. 5,635,517, U.S. Patent No. 7,465,800, U.S. Patent No. 7,855,217, U.S. Patent No. 8,404,717, U.S. Patent No. 8,735,428, and later-issued continuation or method-of-use patents. The asserted set in a particular case depends on the ANDA filing date, the patents listed at that time, and Celgene's litigation strategy.

The early compound patent protection did not determine the entire market-entry date. Celgene extended commercial exclusivity through later patents covering treatment methods, formulations, and manufacturing-related subject matter. This layered approach is common in high-value small-molecule portfolios: once the basic compound patent approaches expiration, later patents can delay unrestricted generic competition if they survive validity and infringement challenges.

What were Teva's Paragraph IV challenges?

Teva's ANDA certification was a Paragraph IV challenge to Celgene's listed patent rights. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.

Teva's filing created several potential defenses:

1. The asserted patent claims were invalid for anticipation or obviousness.
2. Teva's proposed lenalidomide product would not infringe the asserted claims.
3. Certain method-of-use claims could not be enforced against Teva's proposed label or product conduct.
4. Celgene's patents could be vulnerable to written-description, enablement, or double-patenting challenges.
5. Patent expiration or terminal-disclaimer issues could limit the duration of enforceable rights.

The record does not reflect a publicly reported final merits judgment determining that Teva's ANDA product infringed every asserted patent. The case therefore should not be treated as a precedent establishing the validity or enforceability of the entire Revlimid patent estate.

When did Celgene sue Teva over generic lenalidomide?

Celgene filed the action in 2015 in the District of Delaware. The case number indicates that it was opened as civil action No. 1:15-cv-01143. The filing followed Teva's ANDA activity and Paragraph IV certifications concerning generic lenalidomide.

The litigation timing was commercially significant. Revlimid generated substantial revenue for Celgene, and an early generic launch would have affected one of the company's largest products. The case was filed during the period when Celgene was using patent litigation and settlement negotiations to manage the transition from Revlimid exclusivity to controlled generic entry.

How was Celgene v. Teva resolved?

The parties resolved the dispute through a settlement and stipulated dismissal. The public docket does not provide a trial verdict or a publicly adjudicated finding that Teva infringed the asserted patents. The operative settlement terms were not fully disclosed.

Publicly reported settlement terms for Teva and Celgene contemplated a delayed and controlled generic launch rather than immediate unrestricted competition. Teva's later U.S. launch of generic lenalidomide occurred in 2022. The settlement formed part of a broader series of Celgene agreements with generic manufacturers, including arrangements involving supply limitations, launch timing, and restricted distribution.

Resolution issue	Publicly supportable conclusion
Trial verdict	No publicly reported final merits verdict in the case
Settlement	Yes
Public settlement terms	Limited; material commercial terms were confidential or only partly disclosed
Teva market entry	Generic lenalidomide entered the U.S. market in 2022
Immediate unrestricted launch	No
Continuing patent risk	Reduced by settlement, but not equivalent to invalidation of all Revlimid patents

The settlement should be analyzed as a negotiated allocation of launch risk. Teva obtained a path to commercialization, while Celgene obtained additional time to monetize Revlimid and control the rate of generic erosion.

What was the Orange Book status of Revlimid?

Revlimid's Orange Book protection included multiple listed patents with different expiration dates and claim scopes. The key commercial issue was not simply the expiration of the earliest compound patent. Later patents and regulatory exclusivities affected the timing and conditions of generic entry.

The principal Orange Book protections included:

• Core lenalidomide compound protection.
• Patents covering treatment methods for multiple myeloma and related hematologic diseases.
• Patents covering specific dosage regimens and patient populations.
• Formulation and pharmaceutical-composition patents.
• Patents connected to restricted distribution and safe-use administration.

Orange Book listings support the Hatch-Waxman litigation mechanism, but listing alone does not establish validity or infringement. A generic applicant can challenge listed patents through Paragraph IV certifications, and the brand company must prove infringement in litigation.

The Orange Book also does not capture every commercially relevant right. Manufacturing-process patents, trade secrets, regulatory controls, contractual restrictions, and distribution-system requirements can affect generic entry even when they are not listed in the Orange Book.

What exclusivity protected Revlimid beyond patents?

Revlimid received FDA approval in 2005. FDA regulatory exclusivity periods were shorter than the overall patent-protected commercial period. The product's principal long-term protection came from its patent estate, later-issued patents, regulatory strategy, and negotiated generic settlements.

Exclusivity mechanism	Relevance to Revlimid
New chemical entity exclusivity	Applied at initial FDA approval but expired well before the principal generic launch
Orphan-drug exclusivity	Relevant to certain indications and approval periods
Patent exclusivity	Primary long-term barrier to generic entry
REMS and restricted distribution	Did not independently create patent exclusivity but complicated generic commercialization
Settlement agreements	Controlled timing and volume of generic entry

The FDA approved Revlimid for multiple indications over time. Each indication could support separate method-of-use claims and could affect labeling, patent litigation, and the scope of a generic applicant's proposed label.

What formulation patents protected generic lenalidomide entry?

Formulation patents can be important even when the active ingredient itself is no longer protected. A generic applicant may avoid a formulation claim by using a different excipient system, capsule composition, manufacturing process, or dosage form. The analysis turns on the exact claim language and the ANDA product design.

For Revlimid, formulation and product-related protection potentially covered:

• Oral capsule compositions containing lenalidomide.
• Specific strength and dosage configurations.
• Stability and release characteristics.
• Pharmaceutical excipients and capsule materials.
• Solid forms or physical properties of the active ingredient.
• Manufacturing methods used to produce the finished product.

The commercial strength of a formulation patent depends on whether the ANDA product necessarily practices the claim. A broad formulation claim can create substantial risk if the generic's composition is fixed by the ANDA. A narrow claim may be avoidable through a non-infringing formulation or a different manufacturing route.

How strong was Celgene's Revlimid patent estate?

Celgene's patent estate was commercially strong but legally exposed to predictable Hatch-Waxman attacks.

Strengths

• Multiple overlapping patent families.
• Coverage across compound, method-of-use, formulation, and process subject matter.
• High-value indications with substantial revenue.
• Ability to assert patents as new continuation applications issued.
• Restricted distribution requirements that complicated generic launch logistics.
• Settlement leverage created by the cost and duration of Delaware patent litigation.

Weaknesses

• The earliest compound patents faced expiration and validity scrutiny.
• Later patents were more vulnerable to obviousness and claim-scope arguments.
• Method-of-use patents depended on the generic label and inducement evidence.
• Formulation and process patents could be designed around.
• Patent-term and terminal-disclaimer issues could limit effective exclusivity.
• A settlement eliminated the opportunity to test the full estate in a final judgment.

The portfolio's strength was therefore cumulative. No single patent necessarily controlled the entire market. The practical barrier came from the number of patents, the timing of their expiration, the cost of litigation, and Celgene's ability to negotiate launch restrictions.

What generic launch risks existed for Teva?

Teva faced four principal risks.

Regulatory risk

The FDA could delay ANDA approval because of the 30-month stay, unresolved patent certifications, labeling issues, or REMS-related requirements.

Infringement risk

Teva could face damages or an injunction if its proposed product infringed valid and enforceable claims. Method-of-use patents posed particular risks if the proposed label encouraged patented uses.

Supply and distribution risk

Lenalidomide distribution is subject to controlled dispensing and safety-monitoring requirements. Teva needed a compliant distribution system capable of managing prescriptions, pharmacies, patients, and prescribers under the applicable FDA framework.

Commercial timing risk

A settlement could permit entry before complete patent expiry but restrict launch volume or timing. An authorized generic, multiple generic entrants, or staggered settlement dates could reduce the value of first generic entry.

Teva accepted settlement risk in exchange for a defined route to market. Celgene avoided the uncertainty of trial and appeal while preserving a period of branded revenue.

Which companies challenged Revlimid patents?

Celgene litigated Revlimid patents against several generic applicants. Publicly reported disputes involved companies including Teva, Natco, Dr. Reddy's Laboratories, Mylan, and Sandoz.

The generic landscape developed through a combination of:

• Paragraph IV ANDA filings.
• Patent litigation in the District of Delaware.
• Confidential or partially disclosed settlements.
• Authorized or limited generic arrangements.
• Staggered commercial launches.
• Controlled distribution obligations.

The existence of multiple challengers increased pressure on Celgene but also made coordinated settlement structures commercially valuable. Once more than one generic entered, the risk of rapid price erosion increased substantially.

How did the Teva case affect Celgene's revenue exposure?

Revlimid was one of Celgene's largest products before Bristol Myers Squibb acquired Celgene in 2019. Generic entry threatened revenue through price reductions, payer substitution, formulary pressure, and loss of prescription volume.

The impact depended on:

• The number of generic entrants.
• Whether entry was volume-limited.
• Whether Teva launched all strengths simultaneously.
• The timing of additional generic launches.
• The availability of authorized generic supply.
• The pace of physician and pharmacy substitution.
• The continuing use of Revlimid for indications not immediately exposed to generic substitution.

The settlement reduced the risk of an abrupt, all-at-once loss of exclusivity. It did not eliminate the long-term erosion risk. Teva's 2022 launch marked the transition from patent-protected monopoly economics to managed generic competition.

What patent litigation affects Revlimid after the Teva settlement?

The Teva settlement resolved the dispute between Celgene and Teva, but it did not invalidate or extinguish the broader Revlimid patent estate. Other generic applicants could continue to litigate different patents, pursue different ANDA strategies, or enter under separate settlement terms.

The settlement's legal effect was party-specific. It governed Celgene and Teva and did not automatically determine:

• The validity of patents against other defendants.
• The infringement position of other generic products.
• The enforceability of later-issued patents.
• The timing of launches by unrelated generic manufacturers.
• Patent rights outside the United States.

A party-specific settlement is therefore not a substitute for a portfolio-wide validity judgment.

What was the geographic scope of Celgene's Revlimid patent protection?

The case was a U.S. action and addressed U.S. patent rights and U.S. generic approval. It did not resolve patent rights in Europe, Canada, Japan, or other markets.

International protection varied by jurisdiction because of differences in:

• Patent filing and prosecution history.
• Patent-term calculations.
• Supplementary protection certificates.
• Patent validity standards.
• National litigation outcomes.
• Generic approval rules.
• Settlement and competition-law requirements.

The U.S. settlement had no automatic legal effect outside the United States, although Celgene's global commercial strategy and generic launch planning were coordinated across markets.

What manufacturing and intellectual-property barriers affected generic lenalidomide?

Generic manufacturers needed more than an FDA-approved formulation. They required a compliant source of lenalidomide API, validated manufacturing processes, quality-control systems, and a distribution structure compatible with the safety program.

Potential barriers included:

• API manufacturing know-how.
• Control of impurities and degradation products.
• Solid-form control.
• Process patents.
• Stability and packaging requirements.
• Controlled distribution and pharmacy enrollment.
• Product-specific risk-management procedures.
• Patent claims directed to manufacturing or formulation.

Trade secrets and manufacturing know-how can remain commercially significant after patent expiration. They do not normally prevent a capable generic manufacturer from entering permanently, but they can increase development cost and delay launch.

What is the commercial significance of the case?

Celgene Corporation v. Teva Pharmaceuticals USA, Inc. is best understood as a managed generic-entry case rather than a definitive patent-validity decision. The litigation protected Celgene's negotiating position during the transition from Revlimid exclusivity. Teva obtained an economically valuable launch path, but not an immediate unrestricted market opening.

The case demonstrates three features of high-value pharmaceutical patent strategy:

1. A brand company can extend protection through multiple patent families after the core compound patent approaches expiration.
2. A generic company can create substantial settlement leverage through a Paragraph IV filing even without obtaining a trial judgment.
3. The commercial result may turn on launch timing, volume, distribution, and settlement terms rather than the outcome of a single patent claim.

Key Takeaways

• The case was a Hatch-Waxman dispute over Teva's ANDA for generic lenalidomide.
• Celgene asserted Revlimid-related patent rights in the District of Delaware.
• Teva's Paragraph IV challenge created patent litigation and an FDA approval delay mechanism.
• The parties settled and the case did not produce a publicly reported final infringement judgment.
• Teva launched generic lenalidomide in the United States in 2022 under a controlled market-entry framework.
• Celgene's Revlimid protection depended on a layered estate covering compound, formulation, method-of-use, and process subject matter.
• The settlement did not invalidate the broader Revlimid patent portfolio or determine the rights of other generic manufacturers.
• Generic competition created substantial revenue exposure for Revlimid, but the settlement moderated the timing and pace of erosion.
• REMS and restricted distribution requirements created operational barriers separate from patent validity.
• The case has limited precedential value because it ended without a public merits decision.

FAQs About Celgene v. Teva and Revlimid Patent Litigation

When did Teva launch generic Revlimid?

Teva launched generic lenalidomide in the United States in 2022 after resolving its patent dispute with Celgene through settlement.

Did Teva win the Revlimid patent lawsuit?

There was no publicly reported trial verdict awarding Teva a finding that the asserted patents were invalid. The parties resolved the case through settlement.

Was Revlimid's basic compound patent still effective when Teva entered?

The commercial protection at Teva's launch depended on the full patent estate and settlement structure, not only the earliest lenalidomide compound patent.

Is lenalidomide a biologic subject to biosimilar competition?

No. Lenalidomide is a small-molecule drug approved through the ANDA pathway. Its competitors are generics, not biosimilars.

Did the Teva settlement apply to generic manufacturers outside the United States?

No. The case was a U.S. patent action. Its settlement governed Celgene and Teva and did not automatically resolve foreign patent rights or unrelated generic litigation.

References

1. U.S. District Court for the District of Delaware. (2015). Celgene Corporation v. Teva Pharmaceuticals USA, Inc., No. 1:15-cv-01143, docket and pleadings.

2. U.S. Food and Drug Administration. (2005). Revlimid (lenalidomide) approval history and prescribing information. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for Celgene Corporation lenalidomide patent families. USPTO.

5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations, Revlimid. FDA.

6. Bristol Myers Squibb. (2019). Bristol-Myers Squibb completes acquisition of Celgene Corporation. Company release.

7. Teva Pharmaceutical Industries Ltd. (2022). Teva launches generic lenalidomide capsules in the United States. Company release.